- Visibility 409 Views
- Downloads 411 Downloads
- Permissions
- DOI 10.18231/j.ijcbr.v.12.i.2.9
-
CrossMark
Circulating serine peptidase inhibitor, Kunitz type 1(SPINT1) –A biomarker of pregnancies with poor placental function and fetal growth restriction
- Author Details:
-
Divia Paul Aricatt *
-
Joylene Diana D'almeida
-
Ranajit Das
-
Ashwini Prabhu
-
Cleeta Rebeiro
Divia Paul Aricatt *
Joylene Diana D'almeida
Ashwini Prabhu
Cleeta Rebeiro
Introduction: Placental insufficiency and fetal growth restriction significantly contributed to stillbirth risk, particularly in India, where reliable maternal and newborn health statistics were scarce. The aim of this study was to investigate serum SPINT1 levels as a biomarker for detecting placental insufficiency potentially easing the global burden of preventable stillbirths. Therefore, the study’s objective is to assess circulating SPINT1 levels at 28-36 weeks gestation to determine its effectiveness as a biomarker for placental insufficiency.
Materials and Methods: This prospective cohort study recruited 77 pregnant participants through convenience sampling, following ethical approvals and informed consent. Clinical data were collected, and serum SPINT1 levels were measured using enzyme-linked immunosorbent assay (ELISA) during 28-36 weeks of gestation. Postnatal follow-up evaluated neonatal outcomes through APGAR scores, focusing on cases with fetal complications. Statistical analyses were conducted using GraphPad Prism v9.
Results: The highest serum SPINT1 levels were observed at 28 weeks, with a significant correlation found with gestational age (r = 0.54, p = 0.004) and systolic blood pressure (r = 0.45, p < 0.0001). Multiple linear regression identified age, hemoglobin, and blood pressure as significant predictors of SPINT1 levels (p = 0.0022). Low APGAR scores were noted in five cases, indicating a link between impaired neonatal outcomes and placental insufficiency.
Conclusion: Serum SPINT1 had the potential to enhance early detection of placental insufficiency, improving management strategies for high-risk pregnancies. Further research was necessary to confirm these findings and explore broader clinical applications.
References
- Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. BMJ. 2013;346:f108.
- Bellad MB, Goudar SS, Mallapur A, Ramadurg U, Charanthimath U, Katageri G, et al. Maternal and newborn health in Karnataka State, India: the Community Level Interventions for Pre-Eclampsia (CLIP) trial’s baseline study results. PLoS One. 2017;12(1):e0166623.
- Maršál K. Physiological adaptation of the growth-restricted fetus. Best Pract Res Clin Obstet Gynaecol. 2018;46:84–98.
- Alfirevic Z, Stampalija T, Medley N. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev. 2015;(4):CD001450.
- Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, et al. ASPRE trial: incidence of preterm pre-eclampsia in patients Aricatt et al. / International Journal of Clinical Biochemistry and Research 2025;12(2):110-115 115 fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound Obstet Gynecol. 2018;51:738–42
- Cruz‐Martinez R, Savchev S, Cruz-Lemini M, Mendez A, Gratacos E, Figueras F. Clinical utility of third-trimester uterine artery Doppler in the prediction of brain hemodynamic deterioration and adverse perinatal outcome in small-for-gestational-age fetuses. Ultrasound Obstet Gynecol. 2015;45(3):273–8.
- Mali RV, Dalal A, Khursheed R, Gan A. Association of Stillbirths with Maternal and Fetal Risk Factors in a Tertiary Care Hospital in South India. Obstet Gynecol Int. 2021;8033248.
- Tong S, Walker SP, Keenan E, MacDonald TM, Taylor R, McCowan LM, et al. Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies. Am J Obstet Gynecol MFM. 2022;4(4):100618.
- Hong J, Kumar S. Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction. Clin Sci. 2023;137(8):579–95.
- Yu P, Chen S, Wang H. Placental biomarkers of fetal-originated diseases. Placenta Reprod Med. 2024:3.
- Shaikh Z, Pathak R. Revised Kuppuswamy and BG Prasad socio- economic scales for 2016. Int J Community Med Public Health. 2017;4(4):997–9.
- Sharma B, Prasad G, Aggarwal N, Siwatch S, Suri V, Kakkar N. Aetiology and trends of rates of stillbirth in a tertiary care hospital in the north of India over 10 years: a retrospective study. BJOG. 2019;126(4):14–20.
- Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001;344(7):467–71.
- Moraitis AA, Wood AM, Fleming M, Smith GCSS. Birth weight percentile and risk of perinatal death. Obstet Gynecol. 2014;124(2 Pt 1):274–83.
- Kaitu'u-Lino TJ, MacDonald TM, Cannon P, Nguyen TV, Hiscock RJ, Haan N, et al. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. Nat Commun. 2020;11(1):2411.
- Murphy CN, Cluver CA, Walker SP, Keenan E, Hastie R, MacDonald TM, et al. Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction. J Clin Med. 2022;11(4):901.
- Grobman WA, Rice MM, Reddy UM, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med. 2018;379(6):513–23.
- Walker KF, Bugg GJ, Macpherson M, McCormick C, Grace N, Wildsmith C, et al. Randomized Trial of Labor Induction in Women 35 Years of Age or Older. N Engl J Med. 2016;374(9):813–
- Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene. 2007;26(11):1546–56.
- Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, and national levels and trends in mat ernal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet. 2016;387(10017):462–74.
- Ministry of Health and Family Welfare, Government of India. National Health Mission. State Wise Information. 2013. Available from: http://nrhm.gov.in/nrhm-in-state/state-wise- information/karnataka.html
- Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121(1):14–24.
- Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.
- Kodkany BS, Derman RJ, Honnungar NV, Tyagi NK, Goudar SS, Mastiholi SC, et al. Establishment of a Maternal Newborn Health Registry in the Belgaum District of Karnataka, India. Reprod Health. 2015;12(Suppl 2):S2.
- World Health Organization. Improving maternal, newborn and child health in the South-East Asia Region. New Delhi: WHO Regional Office for South -East Asia; 2015. https://apps.who.int/iris/handle/10665/204703
- Payne B, Magee LA, von Dadelszen P, et al. Protocol for CLIP trials. Lancet. 2015. Referenced via ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01911494